Avalere Health’s Post

Are you curious about how trends in real word evidence (RWE) are shaping decision-making in healthcare? Join us at #ISPORAnnual for an insightful research poster tour that includes insights for leveraging RWE in non-oncology submissions in the UK, France, and Germany. Taking place at PT43 on May 7 from 3:30-4:15, we'll provide a brief overview of our findings and engage in a lively discussion with delegates and the knowledgeable tour guide. Discover key insights from our analysis of health technology assessment (HTA) submissions to NICE, HAS, and the G-BA, including: - The prevalence of RWE in non-oncology submissions - Trends in the use and acceptability of RWE across different markets - Various ways RWE is utilized to support clinical effectiveness, tolerance, and cost-effectiveness. Authors: Ally Robert and Vasileios Pardalidis, Avalere Health. Meet us on the poster tour to gain valuable knowledge and contribute to the discussion. Meet us at Booth 413: https://lnkd.in/eAxvzZha #HEOR #MarketAccess #RWE #HTA #WeAreAvalereHealth

🔔 Join DEEP and DiMe today on the last session of the webinar series on Nocturnal Scratch. We will be joined by an exciting panel, including representation from EMA and FDA, to discuss the validation and adoption of the digital measurements of nocturnal scratch. Don't forget to sign-up and join us today at 5pm CEST! FDA European Medicines Agency Digital Medicine Society (DiMe) Takeda GSK Pfizer ActiGraph Genentech #digitalmeasures #collaboration #validation

Don't forget to join today at 5pm CEST to the final webinar of the Nocturnal Scratch series. Today an exciting panel including EMA and FDA will be discussing the validation and adoption of the digital measurements of nocturnal scratch. My collegue John Batchelor will also be sharing how stack model was used during the EMA pilot to facilitate the engagement between the regulators and the applicant team. Sign up if you haven't yet! #webinar #digitalmesures #collaboration DEEP Measures Digital Medicine Society (DiMe)

🌟🌟 We are thrilled to welcome Ilias Pyrnokokis, Head of Value, Access & External Affairs, Chiesi Hellas, a distinguished expert in healthcare access at the upcoming International Conference on Rare Diseases and Orphan Drugs. 🌈🤝He will join the most awaited panel discussion on "Access and Reimbursement Strategies for Orphan Drugs in Europe" on [Friday 1st of March 🕒 14:30 PM - 15:15 PM] 🗓️ Digital. Along with our esteemed panelists he will delve into the challenges, opportunities, and innovative strategies shaping the future of rare disease treatments. 🌍 📌Ilias brings a wealth of knowledge and experience to our discussion on reshaping access and reimbursement strategies for orphan drugs in Europe. Join us as he shares invaluable insights, tackling the challenges and envisioning innovative solutions that can transform the landscape for rare disease patients. 💊 Don't miss this unique opportunity to gain valuable insights and network with industry experts. 🌐 Secure your spot! Registations are still open: https://bit.ly/3HkkWxA 🌍💙Spread the Word: Tag your network, colleagues, and anyone passionate about making a difference in the rare disease community. Let's amplify the impact of this panel discussion on a global scale! #ICORD2023 #rarediseasesconference24 #OrphanDrugs #RareDiseases #HealthcareAccess #PatientAdvocacy #IliasPyrnokokis

In an interview with AJMC - The American Journal of Managed Care during last week’s ISPOR meeting, Blythe Adamson, PhD, MPH, discusses the market forces shaping RWE and how these data may be used as evidence to enhance healthcare value. At Petauri™, generating RWE is a core strength because it is essential to expanding patient access to medical advances. Let's continue the conversation. You can reach us at: https://lnkd.in/ebCSBH8b #medicalaffairs #dataanalytics #ISPOR #HEOR https://lnkd.in/eunPy_7r

Exciting News Alert! We're thrilled to announce the 4th Annual Meeting of #IPcureB, a groundbreaking initiative in the fight against #Hepatitis B! 💪🔬 What is IP-cure-B? It's a visionary five-year project launched in January 2020, led by INSERM in France, uniting 13 dynamic partners across 9 countries, including research institutions, pharmaceutical companies, patient association, and private sectors. And guess what? It's funded by the European Commission under the prestigious #H2020 Programme! 🌍💡 But here's the real scoop: IP-cure-B isn't just any project; it's a game-changer for millions worldwide. 🌎👥 For medical experts: Brace yourselves for a treatment revolution! We're talking novel combination therapies with enhanced cure rates and cutting-edge biomarkers for better patient care. 🩺🔍 For patients: #Hope is on the horizon! We're crafting treatment strategies aimed at the cure, promising shorter durations and a better quality of life, while reducing social stigma. 🌈💊 For communities: It's about time! Our mission? To pave the way for universal treatment access, slashing costs, and easing the global burden of Hepatitis B. 🚀💰 Join us on this extraordinary journey towards a world without Hepatitis B. Together, we can make history! 🌟 #IPCureB #HepatitisB #TreatmentRevolution #GlobalHealth #CureIsPossible 🌐🔑 EU Health and Food Safety European Health and Digital Executive Agency (HaDEA) WHO Regional Office for Europe Robb Butler Ethnikon kai Kapodistriakon Panepistimion Athinon Gilead Sciences European Liver Patients Association Inserm Transfert Karolinska Institutet Institut Pasteur Marko Korenjak Pietro Lampertico @Fabien Zoulim Milan Mishkovikj Veronika Všetíčková European Commission Fédération SOS Hépatites & Maladies du foie ANRS

Are you finding it challenging to prepare for the upcoming changes introduced by the HTAR? Wondering what practical changes your company should consider? Join our webinar for some valuable insights and solutions!

Check out this exciting series!

For HTA/HEOR/RWE professionals.... AOTMiT (Poland) update ---- All previous HTA submissions and decisions are here for the reference. #pricingstrategy #drugprices #marketaccess #hta #reimbursement #oncology #pharmaceuticalindustry #drugdevelopment #heor #rwe https://lnkd.in/dK8JX_j2

Looking to share data from your publication, add a #visualabstract to help it jump out of the page, that's what Antonio Pisani and colleagues did for their new publication looking at patients moving from agalsidase beta to miglastat using the #fabry registry. Their findings indicate variability in long-term outcomes after switching from ERT to migalastat, underscoring the importance of careful monitoring. Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis Antonio Pisani, Kathryn Wilson, Julie Batista, Ilkka Kantola, Alberto Ortiz, Juan Manuel Politei, Laila Al-Shaar, Manish Maski, MD, MMSc, Ana Crespo, Elvira Ponce León, and Aleš Linhart https://lnkd.in/ePYRRuTz Sanofi Fabry International Network